Drug Farm
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An AI-driven biotech using genetics and in vivo models to discover novel drugs for infectious diseases and oncology.
Infectious DiseaseOncology
Technology Platform
The IDInVivo+ platform integrates CRISPR-based in vivo screening in humanized models with AI/ML to identify and validate novel host-targeted drug candidates.
Opportunities
Potential to deliver first-in-class therapies for high-burden diseases like hepatitis B by targeting novel, genetically-validated host pathways.
Risk Factors
High risk inherent in novel target discovery, and the platform's long-term value depends on clinical proof-of-concept for its lead candidates.
Competitive Landscape
Faces competition from global AI-biotechs (e.g., Exscientia, Recursion) and large pharma in-house efforts, but stands out with its integrated in vivo validation focus.